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Specific values of technological properties of excipients allow the establishment of numerical parameters 
to define and compare their functionality. This study investigates the functionality of Polyplasdones XL 
and XL10. Parameters studied included tablet disintegration profiles, compactibility profiles and powder 
flow. The results allowed the establishment of quantitative surrogate functionalities of technological 
performance, such as absolute number, and as a value relative to the known microcrystalline cellulose type 
102. Moreover, the establishment of an explicit functionality to improve the technological performance of 
two diluents and a model drug was investigated, as was setting up of these functionalities, as quantitative 
values, to determine the input variables of each material and its probable functionality in a drug product. 
Disintegration times of pure Polyplasdone XL and its admixtures were around half that of Polyplasdone 
XL10. The improvement in tablet compactibility was 25-50% greater for Polyplasdone XL10 than 
Polyplasdone XL. Crospovidones proportions of up to 10% have little effect on the flow properties of 
other powders, although pure Polyplasdone XL10 and its admixtures display compressibility indexes 
about 20% greater than Polyplasdone XL. The observed results are in line with a smaller particle size 
of Polyplasdone XL10 compared to Polyplasdone XL.
Uniterms: Excipients/functionality. Polyplasdones XL/functionality. Polyplasdones XL10/functionality. 
Tablets/compactibility. Tablets/disintegration time. Tablets/powder flow. Amoxicillin. Magnesium 
stearate. Superdisintegrants.
Os valores específicos de propriedades tecnológicas de excipientes permitem o estabelecimento de 
parâmetros numéricos para definir e comparar a sua funcionalidade. Este estudo investiga a funcionalidade 
dos excipientes. Os parâmetros estudados foram perfis de desintegração dos comprimidos, perfis de 
compactação e fluxo de pó. Os resultados permitiram expressar o desempenho tecnológico através de 
valores absolutos e valores relativos à conhecida celulose microcristalina tipo 102. Do mesmo modo, 
permitiram estabelecer uma funcionalidade explícita para melhorar o desempenho tecnológico de dois 
diluentes e um fármaco modelo. A criação destas funcionalidades, como valores quantitativos, permite 
conhecer as variáveis de entrada de cada material e sua provável funcionalidade em um medicamento. 
Os tempos de desintegração do Poliplasdone XL e das suas misturas são cerca da metade do observado 
para as misturas com o Poliplasdone XL10. Melhoria da compressão de comprimidos que contêm 
Polyplasdone XL10 é 25-50% maior do que o Polyplasdone XL. Crospovidonas em proporções de até 
10% têm pouco efeito sobre as propriedades de fluxo dos outros pós embora o Poliplasdone XL10 e 
suas misturas exibam índices de compressibilidade cerca de 20% maior do que o Poliplasdone XL. Os 
resultados observados estão em sintonia com o menor tamanho de partícula do Poliplasdone XL10, em 
comparação com o Poliplasdone XL.
Unitermos: Excipientes/funcionalidade. Poliplasdones XL/funcionalidade. Poliplasdones XL10/
funcionalidade. Comprimidos/perfil de compactibilidade. Comprimidos/tempo de desintegração. 
Comprimidos/fluxo de pó. Amoxicilina. Estearato de magnésio. Superdesintegrantes.
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INTRODUCTION
C r o s s - l i n k e d  p o l y v i n y l p y r r o l i d o n e s  o r 
crospovidones are synthetic, insoluble, cross-linked 
homopolymers containing less than 1.5% of soluble 
material. Crospovidone particles are granular, highly 
porous and do not form complexes with drugs. These 
disintegrants accelerate tablet disintegration by the 
absorption of great quantities of water when exposed to 
aqueous media. Variation of the medium pH does not affect 
the disintegrant action of crospovidones. Crospovidones 
are used at low concentration levels (2-5%) in direct 
compression, for wet and dry granulation processes 
(Kumar, Nirmala, 2012; Chen et al., 1997).
In contact with water, crospovidone readily forms a 
hydration layer around the particles, gradually filling and 
saturating their internal pores. The cross-linked structure 
of crospovidone behaves as a mesh to prevent the loss of 
water trapped within the internal pores; its mechanism 
of action resembles the sponge model proposed for 
microcrystalline cellulose (Jain et al., 2010).
Crospovidone is one of the three superdisintegrants 
described in the literature. Crospovidone is a disintegrating 
agent at the 2–5% level and is effective in tablets prepared 
using wet granulation. It is considered that its swelling 
properties paired with particle-size distribution enable 
the finer grades of crospovidone to work efficiently in 
fast-disintegrating formulations (Quadir, Kolter, 2006).
Crospovidone is available in several grades differing 
mainly in the particle size, for example Polyplasdone XL 
is a coarser grade while Polyplasdone XL10 is a finer 
grade. The smaller particle size of polyplasdone XL10 
(25-40 µm) generates bulk and tapped densities of 0.3 g/mL 
and 0.5 g/mL, respectively, while Polyplasdone XL, 
with a particle size of 110-140 µm, exhibits bulk and 
tapped densities of 0.3 g/mL and 0.4 g/mL, respectively 
(Polyplasdone, 2013).
The performance of a dosage form is considered to 
be linked to the physical and chemical properties of its 
components. In this case, and as for other components of 
a formulation, crospovidone particle properties play an 
important role in the fabrication and performance of the 
dosage form. The knowledge of the relationships between 
the particle properties and their impact on the process is 
crucial for the development and manufacture of the dosage 
form (Parikh, 2013).
Effective superdisintegrants ideally provide not only 
disintegrant properties but also improved compressibility 
and compatibility and no negative impact on the mechanical 
strength of formulations. In particular, good compressibility 
and flow properties are desirable in a disintegrant.
Generally speaking, tablet quality is quantified 
in terms such as strength, weight, dimensions, and 
active pharmaceutical ingredient content; the required 
properties are produced through control of variables such 
as flowability and tabletability of the mix. This is achieved 
by addressing fundamental issues such as excipient choice 
and the concentration of each component in the final 
formulation (Barrios-Vazquez, Villafuerte-Robles, 2013).
The functional performance of tablet excipients 
is related to their physical, chemical and technological 
properties. It can be assessed using either powder versions 
of the excipients, tablets of pure excipients or formulations 
of a given drug. The first two levels correspond to a 
surrogate functionality that belongs to a pre-formulation 
phase. The knowledge of the surrogate functionality enables 
us to predict whether or not a particular excipient is likely 
to have the requisite functionality to produce a product that 
will meet the finished product specifications in all respects. 
The third level corresponds to the explicit functionality of 
the excipients to develop an appropriate formulation of a 
drug and an effective manufacturing process for the creation 
of a tablet (Díaz-Ramírez, Villafuerte-Robles, 2010).
Functionality is the property that is desirable in an 
excipient to assist in the manufacture and improve the 
conditions of manufacturing, quality or performance of the 
drug. Each formulation or product has its own requirements 
or functionality requirements for an excipient. This means 
that the functionality can only be determined in a batch 
and a specific product. However, it is possible that the 
functionality of the pure excipients could be determined as 
surrogate functionality. It is determined through physical 
and/or physicochemical properties which are critical to 
the typical uses of an excipient. It may also be determined 
using surrogate tests demonstrating the technological 
performance of the pure excipients without a formulation 
or application to a specific drug and product. Among 
the surrogate functional tests concerning technological 
performance, there are compactibility curves, ejection 
pressure curves and curves displaying the disintegration 
properties of the individual excipients. 
Most of the materials used in the industry exhibit 
various mechanical properties. Understanding these 
properties will help to make a formulation decision, such 
as choosing the types of excipients to use, and the final 
evaluation of the dosage form (Parikh, 2013).
Among other factors, powders flow properties have 
been traditionally characterized using a flow through an 
orifice tester or an angular shear cell. The angle of repose, 
Carr’s compressibility index (CI) and the Hausner ratio are 
further commonly used as markers of powder flowability 
(Nalluri, Kuentz, 2010).
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“Although some would consider angle of repose, 
compressibility index, and flow through an orifice to 
be ‘primitive’, there are enough data in the literature to 
indicate that they can be correlated with manufacturing 
experience and because of that they are of some value” 
(Rios, 2006).
Polyplasdone crospovidones are considered 
free-flowing materials and the CI has been reported for 
Polyplasdone XL as 29% (Fujii et al., 2005), 22% (Quadir, 
Kolter, 2006) and 33% (Bühler, 2005), while Polyplasdone 
XL10 was reported to have a CI of 31% (Quadir, Kolter, 
2006), 29.9% (Jain et al., 2010) and 40% (Polyplasdone, 
2013). These different results have been found in the 
literature or calculated from published data for bulk and 
tapped densities and vary because of the different methods 
used to assess the data or due to changes in the excipient 
properties between different batches.
Nevertheless, compressibility indexes from the 
same source always display greater values (lesser fluidity) 
for polyplasdone XL10 than for XL (greater fluidity). 
The results are mostly attributed to the particle size of 
polyplasdones.
One of the procedures used to characterize and 
classify the mechanical properties of pharmaceutical 
materials involves compact testing to derive indexes of 
tableting performance (Nordström et al., 2011). Among 
them, enhanced tablet tensile strength with increasing 
compaction pressure has been used. This showed a 
progressive increase in tensile strength up to a certain 
limit. Thereafter, with increasing compaction pressure, 
the tablet tensile strength was shown to level out. The 
overall compactibility profile tended to be sigmoid in 
shape (Fichtner et al., 2008). Compactibility profiles with 
sigmoid shape have been described using an equation 
based on the Weibull distribution (Eq. 1) (Castillo, 
Villafuerte, 1995a; Castillo, Villafuerte, 1995b). Recently, 
this model has been used to describe the compactibility 
of celluloses as indicative of their functionality as tablet 
excipients (Díaz-Ramírez, Villafuerte-Robles, 2010).
 ln(–ln(1 –D/Dmax)) = n * ln Pc + I Eq. 1
where D denotes the tablet’s hardness or crushing strength, 
Dmax the maximal crushing strength attained, Pc the 
compaction pressure, n the slope of the curve and I the 
intercept of the curve.
Tablets must have sufficient mechanical strength 
to resist crumbling or breaking when being handled and 
processed, especially during packaging. Tablet hardness 
is therefore important and has practical relevance (Ilića 
et al., 2010).
The excipients in a drug product determine the 
characteristics of the final product that should remain 
within certain limits in order for quality assurance to 
approve its release. The quality control attributes (QCAs) 
of a dosage form are linked to raw material attributes 
and process parameters. Linking raw material attributes 
to CQAs is a valuable science-based process that can 
aid in identifying which material attributes and process 
parameters critically affect the product (Miinea et al., 
2009).
The functionality of crospovidones can vary 
according to the formula in which they are used. In this 
sense, it can be useful to test their functionality with tablets 
of drugs that do not disintegrate easily, such as amoxicillin, 
and with excipients representing water soluble (lactose) 
and water insoluble (calcium phosphate) materials. These 
materials are known to display an important degree of 
difference in the effectiveness of superdisintegrants 
(López-Solis, Villafuerte-Robles, 2001).
The objective of this study was to provide a 
bibliographic overview of the quantitative functionality 
of crospovidones in promoting tablet disintegration and 
to evaluate their functionality as excipients for direct 




The materials used in this study were Polyplasdone 
XL (batch 03100261478) and Polyplasdone XL10 (batch 
03100262509) obtained from Ashland-ISP Technologies 
Inc., amoxicillin trihydrate obtained from Química Alkano, 
magnesium stearate and Pharmatose M200 obtained from 
Helm, and calcium phosphate from DROTASA. The drug 
and the excipients were used as received.
Methods
Powders to be processed
The drug and excipients were evaluated as individual 
powders and as mixtures. Powders corresponding to 30 g 
of the mixtures were weighed and mixed in a twin shell 
blender for 25 min, at 26 rpm. Polyplasdones XL and 
XL10 were mixed separately with magnesium stearate 
proportions of 1% and 2%, calcium phosphate proportions 
of 97%, 95% and 90%, Pharmatose M200 proportions 
of 97%, 95% and 90%, and mixtures of amoxicillin 
containing 1% and 2% magnesium stearate at proportions 
of 95% and 97%.
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Disintegration time
Tablets obtained as in the subtitle compactibility 
were used to determine the disintegration time. 
Disintegration time was measured using 900 mL water 
at 37 °C, using the USP disintegration test apparatus 
without the discs (TEMSA-Mexico). The disintegration 
time was taken as the time required for each one of 
three tablets to pass completely through the screen or 
the time required to obtain a soft mass without any hard 
agglomerates. The value is registered as the average of 
three tablets.
Compactibility
Tablets weighing 150 mg were compacted for 10 s in 
a hydraulic press, at a series of compaction pressures from 
27 MPa to 207 MPa and using 8 mm circular flat-shaped 
punch and die. Tablet crushing strength was measured in 
triplicate, registering the results as an average. For this 
purpose, a tablet hardness tester Erweka TBH30 was used. 
The procedure involved placing each tablet diametrically 
between two flat surfaces and applying pressure until 
the tablet breaks down. The results were expressed as 
compactibility curves against the compaction pressure 
used to obtain the tablets.
Powder flow
The equipment used to assess the powder flow is of 
our own fabrication and similar to that used to determine 
the tap density of powders (Kibbe, 2000; Villafuerte, 
2001). The tapper was adjusted at a rate of 50 taps per 
minute and the graduated cylinder was elevated up to a 
height of 15 mm. This device uses a 100 mL graduated 
cylinder joined to a glass funnel with an orifice of 6 mm 
that can be closed using a glass rod. Once the sample has 
been weighed and placed in the closed funnel, the rod is 
removed and the device starts. The time required to empty 
25 g of the powder from the funnel, through the funnel 
orifice, was used to calculate the speed of the powder 
flow. The registered results are the average of 5 repetitions 
with the same sample. The powders were sieved through 
a number 20 mesh after each repetition.
Bulk and tapped density
The bulk (ρb) and tapped density (ρt) of powders 
were determined using the above-mentioned tapping 
machine (n=5). A 100 mL measuring cylinder was filled 
with 25 g of sample. The volumes were recorded at the 
beginning (bulk volume) and after 10 taps. The process 
continued until 3 successive volume measurements 
remained constant (tapped volume). The bulk density 
was calculated as the ratio of mass and initial volume or 
bulk volume, while the tapped density was calculated as 
the ratio of mass and tapped volume. The Carr’s Index or 
compressibility index (CI-%) (Mehta et al., 2012) was 
calculated according to the following equation:





  Eq. 2
RESULTS AND DISCUSSION
Effect of crospovidones on tablet disintegration
Disintegration of pure crospovidone tablets
Figure 1 depicts the effect of an increasing 
compression pressure on the disintegration time of 
crospovidones tablets. Compression pressure increased 
the disintegration time of pure Polyplasdone XL tablets, 
even though all of the tablets disintegrated quite rapidly, 
within 2 min. On the other hand, disintegration times 
of Polyplasdone XL10 tablets remained practically 
unchanged with an increasing compression pressure. The 
addition of magnesium stearate reduced the disintegration 
times of both crospovidones tablets. The compression 
force on crospovidone tablets containing magnesium 
stearate had practically no effect.
The effect of magnesium stearate on the tablets’ 
disintegration time has been ascribed to a loss of affinity 
for water of crospovidone tablets due to the greasy 
hydrophobic domains of the lubricant and to a loss 
of coherence of the tablets because of the mechanical 
weakness of the same greasy domains; the loss of 
coherence of the tablets prevails over the loss of affinity 
for water. As will be shown in the following paragraphs, 
Polyplasdone XL tablets compacted at about 180 MPa 
showed a loss of tablet hardness of about 48% after the 
addition of 2% magnesium stearate. This produced a 
decrease of about 35% in the observed disintegration 
time. In the same way, a loss of tablet hardness of 35% of 
Polyplasdone XL10 produced a decrease of 23% in the 
disintegration time (Figure 1).
The in vitro disintegration time of Polyplasdone 
XL10 was found to be almost twice that of Polyplasdone 
XL. The in vitro disintegration time was rapid for tablets 
containing Polyplasdone XL and somewhat delayed for 
tablets containing Polyplasdone XL10.
Figure 2 depicts tablets of crospovidones and 
their admixtures with magnesium stearate, considering 
the disintegration times calculated by regression for a 
compaction pressure of 178 MPa. Polyplasdones XL and 
XL10 tablets showed the same trend towards decreasing 
disintegration times as the magnesium stearate proportion 
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increased. The faster disintegration of Polyplasdone XL 
tablets may be due to a greater average particle size 
(110-140 µm) and a lower compactibility compared 
to Polyplasdone XL10 (25-40 µm) (Polyplasdone, 
2013).
FIGURE 1 - Effect of magnesium stearate on the disintegration 
profile of the crospovidones tablets Polyplasdones XL and 
XL10.
FIGURE 2 - Effect of magnesium stearate on the disintegration 
time of Crospovidones, Polyplasdones XL and XL10 tablets. 
Points calculated by regression for Pc=178 MPa.
The greater particle size allows a greater powder 
bed porosity and tablet porosity and faster water uptake 
from the medium, swelling and burst effect. Moreover, it 
seems that during compaction, the larger Polyplasdone 
XL particles become more deformed than the smaller 
ones of Polyplasdone XL10. After contact with water, 
Polyplasdone XL particles recover their normal structure, 
producing a greater force of expansion and tablet 
disintegration. Moreover, and as will be shown later, 
Polyplasdone XL tablets display lower compatibilities, 
thereby enabling shorter disintegration times.
The values of  dis integrat ion t ime of  pure 
Polyplasdones tablets, calculated at a compaction pressure 
of 178 MPa, can be used as a measure of functionality, 
or rather a surrogate functionality. In this way, the 
functionality of Polyplasdone XL corresponds with a 
disintegration time of 79 s, while that of Polyplasdone 
XL10 corresponds with a disintegration time of 156 s. 
This indicates greater functionality as the disintegration 
time is shorter.
The greater disintegrability of Polyplasdone XL 
tablets over that of Polyplasdone XL10 has been previously 
observed in tablets of physical mixtures and solid 
dispersions of fenofibrate containing superdisintegrants. 
Tablets of solid dispersions containing Polyplasdone XL 
displayed an average disintegration time of 24.0 min while 
tablets containing Polyplasdone XL10 showed an average 
disintegration time of 30.6 min (Srinarong et al., 2009).
The disintegration behavior of crospovidones has 
been consistently observed in some other cases. Tablets 
of Ludipress LCE showed disintegration times of 73s 
for tablets containing Polyplasdone XL, while tablets 
of the same formulation containing Polyplasdone XL10 
displayed disintegration times of 116 s. In the same 
way and using a second formulation containing aspirin, 
caffeine and paracetamol, tablets containing Polyplasdone 
XL showed a disintegration time of 12 min while tablets 
containing Polyplasdone XL10 showed a disintegration 
time of 22 min (Quadir, Kolter, 2006).
As can be seen, the functionality or disintegration 
properties of Polyplasdone XL are superior to those of 
Polyplasdone XL10. An average of the above-mentioned 
cases reveals that the disintegration times of tablets 
containing Polyplasdone XL are 48% (23-71%) shorter 
than those of tablets containing Polyplasdone XL10.
Effect of crospovidones on tablet disintegration
Among the physical properties of accompanying 
particles that affect the effectiveness of a disintegrant, 
solubility is considered of great importance. The solubility 
of the tableting mixture in water (drug and filler) has a 
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definite influence on the effectiveness of disintegrants; 
disintegrants are more effective in insoluble mixtures. 
Calcium phosphate placebo tablets with 4% crospovidone 
have been observed to disintegrate significantly faster than 
tablets containing lactose (Mohamed et al., 2012).
The effects of tablet formulation solubility 
and hygroscopicity on the dissolution efficiency of 
crospovidone in tablets indicate that highly soluble and/
or hygroscopic ingredients decrease the effectiveness of 
disintegrants in promoting in vitro dissolution (Roche 
Johnson et al., 1991). However, in other cases, only 
hygroscopicity remained valid to decrease the efficiency 
of the disintegrants (Gordon, Chowhan, 1987).
Lactose and dicalcium phosphate have been used 
as fillers by many researchers, representing soluble and 
insoluble tablet matrices, respectively (Mrudula, Derle, 
2011). Therefore, in order to better distinguish between the 
functionalities of different crospovidones, these different 
diluents were used.
Crospovidones lowered the disintegration time 
of Pharmatose M200 tablets after the addition of 3% 
disintegrants. However, the disintegration time of tablets 
increased after the addition of greater proportions of 
the disintegrants (Figure 3). This can be ascribed to 
a double and counteracting effect of crospovidones, 
acting as disintegrants but also as tablet agglutinants. At 
the beginning, the disintegrant effect of crospovidones 
predominates, while the predominance of its effect 
as agglutinant elevates progressively with increasing 
proportions of crospovidones.
The above-mentioned effect has been previously 
observed in Avicel 200 tablets containing Polyplasdone 
XL10 proportions between 0% and 12%. The disintegration 
times began at 90s for pure Avicel tablets, reached a 
minimum at 7% Polyplasdone XL10 (9s) and thereafter 
increased up to 13 s with a Polyplasdone proportion of 
12% (Kasliwal, Singh, 2011).
Once again, the disintegration times of tablets 
containing Polyplasdone XL are about a half (average ≈ 9 s) 
those containing Polyplasdone XL10 (average ≈ 20 s). 
Although there is an improvement in tablet disintegration 
after the addition of 3% crospovidones, the disintegration 
times are within the same range as those reported for 
Pharmatose M200 tablets. Pure Pharmatose M200 tablets 
correspond with zero crospovidone, as depicted in Figure 3.
The effect of crospovidones on Pharmatose M200 
tablet disintegration is relative to lactose solubility. 
Lactose is a freely water soluble substance. The solubility 
of lactose in water is 180 g/L at 20 °C and 18.9 g at 25 °C, 
per 100 g solution. Lactose is freely but slowly soluble in 
water (Lactose, 2013; Machado et al., 2001).
On the other hand, the improvement in disintegration 
time produced by crospovidones on calcium phosphate 
tablets is more important (Figure 4). Tablets of calcium 
phosphate do not disintegrate completely after 30 min. 
After the addition of crospovidones, the disintegration 
time is reduced to an average of about 4 s.
The differential effect of crospovidones on the 
disintegration of Pharmatose M200 and calcium phosphate 
tablet matrices has been ascribed to their water solubility. 
It is believed that a water soluble excipient competes with 
the disintegrant for the available water inside the tablet. In 
fact, it has been observed that Starch 1500, working as an 
active disintegrant, and Pharmatose DCL11, as a passive 
dissolving disintegrant, displayed mutual inhibition to 
promote norfloxacin tablet dissolution. On the other hand, 
the addition of mixtures of Starch 1500 and the insoluble 
diluent calcium phosphate potentiated the disintegrant 
effect to promote norfloxacin dissolution (López-Solis, 
Villafuerte-Robles, 2001).
The results obtained in this study agree with 
the above-mentioned data registered in the literature. 
An insoluble excipient like calcium phosphate, 
with a solubility of 20 mg/L water (Calcium and 
Water, 2013), favors the disintegrant proficiency of 
crospovidones compared to a soluble excipient like 
Pharmatose M200.
Of particular note is the fact that the two different 
crospovidones do not show the previously mentioned 
greater ability of Polyplasdone XL over Polyplasdone 
XL10 to disintegrate tablets. The disintegrant ability of 
both excipients is practically the same on tablets of the 
FIGURE 3 - Effect of crospovidones Polyplasdones XL and 
XL10 on the disintegration time of Pharmatose M200 tablets. 
Points calculated for a compaction pressure of 163 MPa.
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FIGURE 4 - Effect of crospovidones Polyplasdone XL and 
XL10 on the disintegration time of Calcium Phosphate tablets, 
calculated for Pc=163 MPa.
water insoluble calcium phosphate. This can be attributed 
to the exceptionally fast disintegration times.
As previously seen for Pharmatose M200 tablets, 
the addition of crospovidones to calcium phosphate 
tablets decreases the disintegration time. However, 
after attaining a minimum, increasing proportions 
of the added crospovidones produced increasing 
disintegration times.
Figure 5 depicts the effect of compaction pressure 
and crospovidones proportion on the disintegration 
time of amoxicillin tablets containing a lubricant. In 
this case, tablet disintegration times were increased in 
tablets containing a greater proportion of the lubricant. 
Moreover, the disintegration times of tablets containing 
5% crospovidones exhibit shorter disintegrations times 
than tablets containing 3% disintegrant.
The disintegration profiles of amoxicillin tablets 
(Figure 5) can be ascribed to an increasing deformation 
of crospovidone particles, with the subsequent stronger 
recovery after interaction with water, and to decreasing 
tablet porosity as the compaction pressure increases. 
Polyplasdone was reported to exhibit a high capacity 
to retain deformation during post-compression (Zhao, 
Augsburger, 2005). The rapid swelling and disintegration 
of these tablets upon wetting may be partly attributed 
to the recovery of deformation. These counteracting 
effects produce a disintegration profile attaining first a 
FIGURE 5 - Effect of Polyplasdone XL and compaction pressure 
on the disintegration profile of Amoxicillin tablets containing 
1% and 2% magnesium stearate.
FIGURE 6 - Effect of crospovidones on the average disintegration 
time of amoxicillin tablets containing magnesium stearate. 
Calculated for tablets compacted at 163 MPa.
minimum and then an increasing disintegration time as 
the compaction pressure increases.
Considering an average disintegration time of 
amoxicillin tablets containing different proportions 
of magnesium stearate (0, 1 and 2%) at a compaction 
pressure of 163 MPa, Figure 6 depicts the effect of 
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the type of crospovidone on the disintegration time 
of amoxicillin tablets. In the same way as seen for 
Pharmatose, the disintegration times are greater in 
tablets containing Polyplasdone XL10 (average of 50 s) 
compared to tablets containing Polyplasdone XL (average 
of 18 s). It is noteworthy that the higher disintegration 
times of Pharmatose M200 and amoxicillin tablets 
containing Polyplasdone XL10 over those of tablets 
containing Polyplasdone XL are in line with the higher 
crushing strengths displayed by tablets containing 
Polyplasdone XL10. These data will be shown later when 
the compactibility of crospovidones is discussed.
Similar disintegration results were observed for 
oral disintegrating Cetirizine HCl-coated granule tablets 
containing different amounts of Polyplasdone XL and 
XL10 (Douroumis et al., 2011). Tablets containing 
Polyplasdone XL10 showed approximately 22% higher 
disintegration times (average of 7.26 s) than those 
containing Polyplasdone XL (average of 5.67 s). This 
occurs in spite of cetirizine HCl tablets containing 
Polyplasdone XL, which show a compactibility that is 
approximately 12% higher (average of 4.79 kP equivalent 
to 47.0 N) than those containing Polyplasdone XL10 
(4.25 kP equivalent to 41.7 N). In such work, tablets were 
obtained at compaction forces of 4 kN, 8 kN, 10 kN and 
12 kN, containing 2%, 5%, 10% and 20% Polyplasdone.
The disintegration times of amoxicillin tablets are 
higher than those of Pharmatose M200 tablets, although 
lactose is much more water soluble (180 g/L at 20 °C) than 
amoxicillin (3.43 g/L water) (Lactose, 2013; Machado 
et al., 2001). This apparent failure of the statement “the 
greater the overall hygroscopicity and solubility of the 
tablet formulation, the larger the decrease in the efficiency 
of the disintegrant” can be ascribed to the fact that 
lactose is slowly soluble in water. Moreover, the greasy 
hydrophobic magnesium stearate particles contained by 
amoxicillin tablets, that are not present in Pharmatose 
M200, also contribute to increased disintegration times.
In conclusion, the functionality of Polyplasdone 
XL10 as a disintegrant (average disintegration time (DT) 
= 156 s) is about a half that of Polyplasdone XL (average 
DT = 79 s), mostly due to its smaller particle size, the 
smaller tablet porosities produced and the increased 
tablet hardness. Disintegration times of crospovidones 
decrease after the addition of magnesium stearate, 
presumably because of a loss of coherence of the tablets. 
Increasing proportions of crospovidones first reduce the 
disintegration time of different tablet matrices and then 
increase the disintegration times. This is probably due to 
their counteracting disintegrant and agglutinant properties. 
Increasing compaction pressures first decrease and then 
increase the disintegration time of amoxicillin tablets. 
This is attributed to a progressive decrease of porosity and 
increasing deformation of crospovidone particles, which 
is recovered after contact with water.
Effect of crospovidone on tablets compactibility
In addition to the active pharmaceutical ingredients, 
tablets also contain functional ingredients that are 
necessary to bulk out the actives or modify the quality and 
processing properties of the tablet. Various excipients aid 
in compacting the drug during the tableting procedure as 
they do not always possess good compactibility. Important 
tableting process parameters include a high capacity for 
compression and consolidation of materials.
Compactibility of crospovidone tablets
The tablet crushing strength increased up to a certain 
limit by increasing compaction pressures; thereafter, 
the tablet crushing strength leveled out. Compactibility 
profiles with a sigmoid shape, like those shown in Figure 7, 
have been described with an equation based on the Weibull 
distribution (Eq. 1).
The compactibility curves obtained describe the 
relationship between the hardness or crushing strength 
of the tablets and the compaction pressure used to 
obtain them. Figure 7 shows the experimental points 
and calculated regressions, according to Eq. 1, for the 
FIGURE 7 - Effect of magnesium stearate on the compactibility 
profile of Polyplasdone XL tablets. 
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decreases and vice versa. Materials such as Starch 1500 
displayed a lubricant sensitivity as high as 0.53, while 
this was only 0.31 for a type of rice starch, equating to a 
reduction of tablet hardness of 51% and 31%, respectively, 
after lubrication of the powders. These values were 
determined using a lubricant content of 1% (Ahmad et 
al., 2012).
The average lubricant sensitivity of Polyplasdones 
XL and XL10, expressed as the fraction or percentage of 
the reduction of the tablet hardness, is 0.226 and 0.416 
in the presence of 1% and 2% of magnesium stearate, 
respectively. These values were determined by taking 
the maximal tablet hardness (Dmax) calculated from 
compactibility profiles as a reference (Figure 7). This 
showed a decrease of compactibility of 22.6% and 41.6%, 
respectively. These results are in line with materials 
compacting by plastic deformation. The average lubricant 
sensitivity of crospovidones, containing 1% magnesium 
stearate (22.6%), is significant but smaller than that 
observed by Starch 1500 (51%) and rice starch (31%).
Effect of crospovidone on compactibility of tablets
Pharmatose M200 tablets containing varying 
amounts of crospovidones were prepared under the 
same conditions of compaction pressure as those of the 
pure disintegrants. The tablet crushing strength was also 
FIGURE 8 - Effect of magnesium stearate on the calculated 
compactibility (Pc=207 MPa) of Crospovidones, Polyplasdone 
XL and XL10.
compactibility of Polyplasdone XL and its admixtures 
with magnesium stearate.
The  compac t ib i l i t y  o f  Po lyp la sdone  XL 
(Dmax = 392 N) and polyplasdone XL10 (Dmax=314 N) 
tablets is high compared to some other excipients, such 
as GalenIQ 720 (agglomerated isomalt), with a Dmax of 
134 N, and Helmcel 200 (microcrystalline cellulose type 
102) with a Dmax of 357 N. These values of Dmax were 
obtained using tablets with the same geometry and weight 
and measured by the same method (Samayoa-Sandoval, 
Villafuerte-Robles, 2013). These values are considered the 
surrogate functionalities of the excipients as agglutinants 
for direct compression. In this sense, Polyplasdone XL 
and XL10 display functional properties not only as a 
disintegrant but as a direct compression agglutinant. 
Their functionality as a direct compression agglutinant 
is similar to that of microcrystalline cellulose type 102 
(Helmcel 200) and almost more than the double of that 
of GalenIQ 720.
Crospovidones are considered more compactible 
than other superdisintegrants, producing tablets with 
high breaking force and low friability. It has been found 
that Polyplasdone crospovidones possess significantly 
higher breaking force than superdisintegrants such as 
croscarmellose sodium and sodium starch glycolate 
(Polyplasdone, 2013).
After addition of the lubricant magnesium stearate, 
the tablet crushing strength of both crospovidones shows 
a tendency to decrease as the proportion of the lubricant 
increases (Figure 8). This effect is common for polymeric 
materials compacting by particle deformation. The 
compactibility of Polyplasdone XL, determined as the 
maximal tablet crushing strength (Dmax), is 392 N and 
reduces its magnitude to 252 N after the addition of 1% 
magnesium stearate and to 206 N after the addition of 2% 
magnesium stearate.
The mechanism behind a decrease in tablet crushing 
strength is thought to be a lubricant coating the particles of 
drugs and excipients, interrupting interparticle bonding. 
Increasing proportions of lubricants more efficiently 
interrupt this bonding, reducing the tablet crushing 
strength to a greater extent. Materials that are compacted 
by particle deformation are more affected, while materials 
that are compacted by fragmentation are less or not at all 
affected due to the formation of new clean surfaces after 
fragmentation.
Magnesium stearate is a commonly used lubricant 
in pharmaceutical formulations. However, some 
pharmaceutical excipients have shown sensitivity to 
this material when compacted. It has been found that 
this sensitivity decreases as the ductility of the materials 
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determined under the same measurement conditions. 
Increasing proportions of the cross-linked polymers, 
up to 10%, increased the tablet crushing strength; 
tablets containing Polyplasdone XL displayed lower 
compactibilities than tablets containing Polyplasdone 
XL10. Figure 9 depicts the maximal tablet crushing 
strength (Pc=207 MPa) as a function of the crospovidone 
content, which was calculated by regression.
The explicit functionality of Polyplasdone XL, 
as a direct compression agglutinant of a water soluble 
matrix of Pharmatose M200, is defined by compactibility 
improvement obtained. Pharmatose M200 tablets 
increase their tablet crushing strength by about 3.8 N per 
percentage point of added Polyplasdone XL. Also, the 
addition of every percentage point of Polyplasdone XL10 
to Pharmatose M200 tablets improves their compactibility 
by about 6.0 N. Related to the original compactibility 
of Pharmatose M200 (65 N), this means an increase in 
compactibility of about 5.8% and 9.2%, respectively.
A similar functionality of Polyplasdone to 
improve tablet compactibility has been observed by 
frusemide tablets. Polyplasdone improved the tablet 
compactibility, in a range of 4-7 N per percentage point 
of the superdisintegrant added, which was dependent 
on the compaction force used to generate the tablets. 
Considering a compaction pressure of 10 ton the original 
compactibility was 203 N and increased by about 4.8 N per 
percentage point crospovidone added. This is equivalent to 
an increase of about 2.3%. These results were calculated 
from published data (Chaulang et al., 2012).
In the same way, Polyplasdone XL also improved 
the compactibility of meclizine tablets (3.7 kg/cm2) by 
0.1 kg/cm2 per percentage point of the added disintegrant. 
This is equivalent to an increase of about 2.7% (Goyani 
et al., 2012).
The effect of Polyplasdone on the tablet crushing 
strength of a water insoluble matrix such as calcium 
phosphate is depicted in Figure 10. Calcium phosphate 
matrices also increase their tablet compactibility after 
the addition of Polyplasdone. However, the increase is 
much smaller than that seen for matrices of Pharmatose 
M200. In this case, the tablet crushing strength increases 
by 0.8 N and 1.2 N per percentage point of the added 
crospovidones Polyplasdone XL and XL10, respectively. 
Considering the original compactibility of calcium 
phosphate tablets (78 N), this increased by about 1.0% 
and 1.5% per percentage point of crospovidone added, 
respectively.
As can be seen in Figure 11, crospovidones increase 
the compactibility of amoxicillin tablets. This figure 
displays the experimental points and the curves calculated 
by regression according to eq. 1 for amoxicillin tablets and 
tablets of amoxicillin with 5% Polyplasdone XL and 2% 
magnesium stearate added. The Dmax value of amoxicillin 
FIGURE 9 - Effect of crospovidones Polyplasdones XL and 
XL10 on the compactibility of Pharmatose M200. Points 
calculated by regression for Pc=207 MPa.
FIGURE 10 - Effect of crospovidones Polyplasdone XL and 
XL10 on the compactibility of Calcium Phosphate. Points 
calculated for Pc=207 MPa.
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FIGURE 11 - Effect of 5% Polyplasdone XL on the compactibility 
profile of amoxicillin tablets containing 2% magnesium stearate.
tablets increases from about 72 N to 105 N after the 
addition of Polyplasdone XL and magnesium stearate.
Figure 12 depicts the effect of crospovidones on 
the compactibility of amoxicillin tablets, expressed as 
the average compactibility calculated by regression 
for Pc=136 MPa. The functionality of crospovidones 
Polyplasdone XL and XL10 to increase the compactibility 
of amoxicillin tablets is about 9 N and 12 N per percentage 
point of Polyplasdone XL and XL10 added, respectively. 
This equates to an increase in compactibility of amoxicillin 
tablets (59 N) of 15% and 20% per point of crospovidone 
added, respectively.
The absolute values, as well as the relative ones, with 
regard to the improvement in compactibility produced by 
crospovidones are higher for amoxicillin tablets (average 
of 10.5 N; 17.5%), followed by Pharmatose M200 tablets 
(average of 4.9 N; 7.5%) and calcium phosphate tablets 
(average of 1.0 N; 1.2%).
The agglutinant effect of Polyplasdone depends 
on the tablet matrix and can be more or less important. 
Anyway, Polyplasdone has shown a positive effect on 
tablet hardness, irrespective of the concentration used. 
However, it has been reported that increasing proportions 
of the cross-linked polymer (1-10%) did not influence 
crushing force or the friability of acetaminophen tablets 
(Salem et al., 1995).
According to the presented data, Polyplasdone XL10 
displays a mostly greater positive effect on compactibility 
FIGURE 12 - Effect of crospovidones Polyplasdone XL 
and XL10 on the average compactibility (Pc=136 MPa) of 
amoxicillin tablets containing magnesium stearate (1% and 2%).
than Polyplasdone XL, although it has also been observed, 
by oral disintegrating Cetirizine HCl-coated granule 
tablets, that tablets containing Polyplasdone XL show 
approximately 12% higher average compactibility 
(average of 4.8 kP) than those containing Polyplasdone 
XL10 (average of 4.2 kP). However, this contrasts with 
the disintegration times of tablets of this drug containing 
Polyplasdone XL10 (average of 7.3 s), which were higher 
than those of tablets containing Polyplasdone XL (average 
of 5.7s). These tablets were obtained at compaction forces 
of 4 kN, 8 kN, 10 kN and 12 kN and containing 2%, 5%, 
10% and 20% Polyplasdone (Douroumis et al., 2011).
In conclusion, the compactibility of crospovidones 
is similar to that of a direct compression agglutinant 
(Helmcel 200); their average surrogate functionality is 
Dmax=353 N, while that of microcrystalline cellulose type 
102 (Helmcel 200) is Dmax=375 N and that of a direct 
compression excipient, GalenIQ 720, an agglomerated 
spherical isomalt for direct compression applications, is 
Dmax=134 N (Samayoa-Sandoval, Villafuerte Robles, 
2013). Although crospovidones are lubricant-sensitive 
(average of 0.23), they are less sensitive than other 
excipients, such as starch 1500 (0.53) and rice starch 
(0.31). The ability to improve the compactibility of 
different tablet matrices (Pharmatose M200, calcium 
phosphate, amoxicillin+magnesium stearate) is always 
greater for Polyplasdone XL10 (25-50%) than for 
Polyplasdone XL.
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Effect of crospovidones on powder flowability
Flowability of crospovidones
Figure 13 depicts the results obtained for the 
compressibility index of crospovidones and their 
admixtures with magnesium stearate. As expected, 
Polyplasdone XL10 exhibits a greater compressibility 
(32%) compared to Polyplasdone XL (19%). This equates 
to a better powder flow of Polyplasdone XL compared to 
that of Polyplasdone XL10.
Compared  to  some  o the r  exc ip ien t s ,  t he 
compressibility index of microcrystalline cellulose 
type 102 (Helmcel 200), determined under the same 
experimental conditions as those employed here, 
was 21.7%. In the same way, the compressibility of 
agglomerated isomaltose (GalenIQ 720) was determined 
to be 13.8% (Fuentes-Gonzalez, Villafuerte-Robles).
If the compressibility index of crospovidones is 
referred to Helmcel 200, Polyplasdone XL10 displays a 
relative powder compressibility of 1.49, or 49% greater 
compressibility than Helmcel 200, while Polyplasdone 
XL shows a relative powder compressibility of 0.87 or 
a powder compressibility that is 17% smaller than that 
of Helmcel 200. Microcrystalline cellulose type 102, an 
innovator of Helmcel 200, is considered to be at the limit 
of the processability of powders in a high-speed tableting 
machine (Sun, 2010). If that is the case, Polyplasdone XL 
can be processed without problems, while Polyplasdone 
XL10 will need the addition of a glidant.
The effect of the widely used lubricant magnesium 
estearate on the flow properties of Polyplasdone powders 
is a decrease of fluidity or a small increase in powder 
compressibility (Figure 13). The trend curves suggest that 
the soft particles of the lubricant around the polyplasdone 
crospovidones particles deteriorate the powder fluidity 
of the binary mixtures to some extent. With regard to the 
contrasting flowing properties, Polyplasdone XL powder 
displays greater particle size, and seems to be slightly 
more sensitive to the effects of magnesium stearate than 
Polyplasdone XL10, which shows a smaller particle 
size. This is shown by the slope of regression lines of 
polyplasdone XL (3.15) and Polyplasdone XL10 (1.95). 
The greater surface area of Polyplasdone XL10 seems to 
permit the inclusion of more lubricant particles before they 
obstruct the powder flow.
It has been observed that magnesium stearate 
improved the powder flow of spray-dried lactose, until 
a threshold was reached, at which point the addition of 
lubricant had no effect (Morin, 2012). However, with 
lactose 313, higher amounts of magnesium stearate did not 
allow the permanence of the improved powder flowability. 
When a greater than optimum amount of magnesium 
stearate is added, flow properties deteriorate (Hou, Sun, 
2007). In the same way, it has been observed that the 
powder flow of GalenIQ 720 attains a maximum with 
0.4% magnesium stearate (Fuentes-Gonzalez, Villafuerte-
Robles).
It seems that 1% and 2% magnesium stearate are 
above the optimal proportion of the lubricant to improve 
the powder flow of crospovidones. Magnesium stearate 
deteriorates the crospovidone powder flow, at both of the 
proportions of the lubricant used; this is expressed as an 
increase in compressibility index.
Effect of crospovidones on the powder fluidity of 
blends
Flowability of blends is essentially complex, 
since flow properties are not only influenced by the 
physicochemical material factors, but also to a great extent 
by the particle packing (Nalluri, Kuentz, 2010).
Figure 14 depicts the compressibility index of 
mixtures of calcium phosphate and crospovidones as a 
function of the Polyplasdone content. A slight decrease in 
the compressibility index can be observed, which suggests 
a slight increase in powder fluidity as the Polyplasdone 
content increases. The poor powder flow of calcium 
phosphate (CI=47%) is practically unchanged after the 
addition of up to 10% Polyplasdone crospovidones. 
Similar results can be observed for Pharmatose M200 
mixed with different proportions of crospovidones. Figure 
15 depicts the compressibility index of Pharmatose M200 
FIGURE 13 - Effect of magnesium stearate on the compressibility 
of powders of the crospovidones Polyplasdone XL and XL10.
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FIGURE 14 - Effect of crospovidones Polyplasdone XL and 
XL10 on powder compressibility of calcium phosphate.
as a function of the added proportion of crospovidones. 
The poor powder flow of Pharmatose M200 (CI=42%) 
improves after the addition of crospovidones to some 
extent. This occurs in a slightly higher magnitude for 
Polyplasdone XL compared to Polyplasdone XL10. This 
improvement of powder flow agrees with the greater 
powder flow of Polyplasdone XL compared to that of the 
type XL10 (Figure 13).
In contrast to the above-mentioned cases of 
calcium phosphate and Pharmatose M200, the addition 
of Polyplasdone to amoxicillin containing magnesium 
stearate as a lubricant increases the compressibility index 
of the mixtures. This results in a lesser powder flow of 
amoxicillin containing magnesium stearate after the 
addition of crospovidones (Figure 16). This circumstance 
agrees with the increase in powder compressibility 
observed for crospovidones blended with magnesium 
stearate. In the first instance, the ability of crospovidones 
to increase the compressibility index of amoxicillin 
formulations can be attributed to a similar interaction 
with magnesium stearate, as mentioned above for 
crospovidones alone. Moreover, the compressibility index 
of mixtures containing Polyplasdone XL displays lower 
values than Polyplasdone XL10. This results in a greater 
powder flow of mixtures containing Polyplasdone XL 
compared to those containing Polyplasdone XL10. This 
is in line with the powder compressibility observed when 
using mixtures of crospovidones with Pharmatose M200 
(Figure 15).
FIGURE 15 - Effect of crospovidones Polyplasdone XL and 
XL10 on the powder compressibility of Pharmatose M200.
FIGURE 16 - Effect of the crospovidones Polyplasdone XL and 
XL10 on the powder compressibility of amoxicillin containing 
1% and 2% magnesium stearate.
The amoxici l l in powder f low, determined 
using a funnel with an opening of 6 mm, shows a 
reduction of flowability after mixing with magnesium 
stearate and crospovidones (Figure 17), confirming the 
previously mentioned results for powder compressibility 
(Figure 16).
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Also, in Figure 17, a higher flowability of mixtures 
containing Polyplasdone XL compared to those containing 
Polyplasdone XL10 can be observed, confirming the 
previously mentioned results of powder compressibility 
(Figure 16).
Amoxicillin powder flow (2.59 g/min) decreases 
in flowability by about 31% after the addition of 
Polyplasdone XL, up to 1.78 g/min, while a reduction in 
flowability of about 43%, up to 1.47 g/min, is seen after 
the addition of Polyplasdone XL10.
To conclude, crospovidone proportions up to 10% 
have little effect on the flow properties of some other 
excipients and drugs, slightly increasing the powder flow 
of some excipients. However, the addition of magnesium 
stearate to crospovidones reduces their powder flow as 
excipients alone as well as in formulations containing 
FIGURE 17 - Effect of Polyplasdone XL on the average powder 
flow, through an opening of 6 mm, for amoxicillin containing 
1% and 2% magnesium stearate.
crospovidones. Contrasting the flow functionality of 
crospovidones, Polyplasdone XL displays a mostly greater 
powder flow (average of above mentioned formulations, 
CI=37.3%) than Polyplasdone XL10 (average of 
CI=44.8%). Polyplasdone XL appears to be more sensitive 
to magnesium stearate, reducing its flowability to a greater 
extent (increase of about 37% in compressibility index) 
than Polyplasdone XL10 (increase of about 13% in 
compressibility index). This behavior is attributed to the 
smaller particle size of Polyplasdone XL10, displaying 
greater interparticle friction and a greater surface area to 
distribute the added magnesium stearate, diminishing its 
negative effect on its flowability.
Table I summarizes all of the parameters studied. The 
outcomes are presented as averages of the results obtained 
by the different types of formulations. The influence of 
crospovidone type can be compared individually for each 
type of formulation, containing magnesium stearate, 
Pharmatose M200, calcium phosphate or amoxicillin.
CONCLUSION
The functionality of crospovidones Polyplasdone 
XL and XL10 has been found to be different. The current 
results and those found in the literature are coincident, 
showing a similar qualitative functionality, but different 
quantitative functionality, of the Polyplasdones XL and 
XL10. Generally, Polyplasdone XL tablets display shorter 
disintegration times than Polyplasdone XL10 by about a 
half. The disintegration times are in line with a 25-50% 
higher ability of Polyplasdone XL10 to improve the 
compactibility of other materials compared to Polyplasdone 
XL. The higher compactibility of Polyplasdone XL10 
delays the disintegration times. Nevertheless, both 
excipients are highly functional as disintegrants and dry 
agglutinants. Their agglutinant functionality is similar 
to the known functionality of microcrystalline cellulose 
type 102. Also similar to microcrystalline cellulose 
is the sensitivity of crospovidones to magnesium 
TABLE I - Crospovidone functionality considering the disintegration time (DT), tablet crushing strength (TCS) and compressibility 




XL 10 XL XL 10 XL XL 10 XL XL 10 XL
+MS +Pharm +CPh +Amoxi
DT (s) 150.7 60.3 19.5 8.9 2.6 4.7 49.6 17.7
TCS (N) 245.5 227.5 106.0 90.3 90.7 82.7 112.0 100.0
CI (%) 34.9 25.5 41.3 38.5 46.1 45.5 50.0 43.4
MS: magnesium srearate; Pharm: Pharmatose M200; CPh: calcium phosphate; Amoxi: amoxicilin.
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stearate, although it is less than that shown by other 
superdisintegrants like Starch 1500. The flow properties 
of Polyplasdone crospovidones are also different, although 
their impact on other pharmaceutical materials is not of 
great consequence in the usual proportions in which they 
are used. Nevertheless, Polyplasdone XL10 displays about 
20% greater compressibility indexes than Polyplasdone 
XL. This means a good flowing Polyplasdone XL, while 
Polyplasdone XL10 will need the addition of glidants. 
These properties of Polyplasdones are related to the 
smaller particle size of Polyplasdone XL10 compared to 
Polyplasdone XL.
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